MedTrace Logo

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg

NCT00383929 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1979

Last updated 2008-03-20

No results posted yet for this study

Summary

In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5 mg to that of candesartan 32 mg alone in patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and candesartan/HCT 32/12.5 mg with that of candesartan 32 mg, respectively.

Conditions

Interventions

DRUG

Candesartan cilexetil

32mg oral

DRUG

Hydrochlorothiazide

12.5 mg oral

DRUG

Hydrochlorothiazide

25 mg oral

Sponsors & Collaborators

Principal Investigators

  • Established Brands HTN/CHF Medical Sience Director, MD · AstraZeneca

  • Gerd Bonner, MD · MEDIAN Kliniken Bad Krozingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-08-31
Completion
2007-10-31

Countries

  • Denmark
  • Estonia
  • France
  • Germany
  • Lithuania
  • Netherlands
  • Poland
  • Serbia and Montenegro
  • Sweden
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383929 on ClinicalTrials.gov